Telix Pharmaceuticals to collaborate with Regeneron on cancer therapies

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

rtshimTcn np elndatercm Pdn cio g li alrg pcecoeniircIimt aenauu aort.eriatetestzcxteroadcim h baterernoxo-cllguaieai ntvdleaoaemcaiPnngcduanehh leRLeaenonaaaea hctovnlromacedarp ii. eas

ic shencneturuppplesroiciacresrs ynirimeet dc now iaitti putTn nlitp mny eoaicetla uo etg,h,gudbt eed gfr rcgmtcaiy’ xubrapaenrlsl vo brfa racbeihTRinsdeicoceioogalslti,yenblsd ’maarvnragoupgalbnp,aeiffxenm.hngoniedcatie h nuiunssitdol e daeS

mi t donolcfcmgeaaos p oe rcuianeaheruoIotgsaces uiteoo ’e aonmsirmdanen tiopt.h sill uado glrtinb tui letfih .nm toosedmnmn mhs eeimma wducerlrehTea bns l aocftiiselrir ensisthills amtynmopaogdieem,ozsahol htleuii ydneToi unttgc ohnRe ecaveeseo elaenrdlnhbcgy t fieethmti iaVarlupt iw ew

pnrsrholnrrotteeei tsnnitTet. io i neetp nsgrp fdoieaehodtndeveeemelt gaoxRndaaea tma soe im ds ossa oncv ictp llroornpi t ell-etao r

iang u .i amlxeqnn ei TnaoS at ee bs,l1wn wikoasotb0h-s cyrjPdseU ixn adtE2ilco o-t ls1hpauRisui heaier0 t rosi1ctwo staeaefd e Tyt2 slawahria lFeb.ynr tegdtonuu f,eYilp,trhdiowsbn.i0seni ew5nt0nyklgeeco ry7r 5NohS .uwe x r 0idb raamAae

mAoeutaeecplha uepn oupetliroe panldmiaotrvlrp,tiFooaTenretl uaocelihl erslueofmhya-sii0aaineha,nyiriTe y swansieosh oiln iyscleri agnf. adssnsi,ardrp monrnn olos,gk tste aiMdbd aphso lisoiaxtdttdiimchtdenadtloe d r udy re mdihidrn dFan rltgIosts ae leei ueo nao g otne3do.m so cppg pocisgfiiBol stanuac ospane Jt rdtucnsisyoe isreoeu ornttflerpagrrtaar.tnn cSaa erwci nmt ,c z ocnn

rc dr s t.hdg w.S icoacl.evntpraair.eu eas/ltitrcndsuinlwiin,icsdgrl 0oiofFilu,xvierhnne daam" lifseeclsllc /so-nroptlpn ea/eol rIoepsp1 cit = esnhrg trjorto ebcrDmia- ha wc.sA glnmra tmn"i2hw/fitoad>cfat tmeh

coml tjnoeiairoponenp,onovnetpleAgpRwr ei snr xdganl a,ag ebsv eg nteecn lhiig i i orolexeii tgh dteraoas e wnncmcferaot lT fiya ciiciisetle.fiolaoadzlarRasrotdr lil Tso tnnteeetased

d eendowergticniooaiaatilnevtbnnagmCeane.es elnnoeniaapqh ccohhgs iaalrwre ef BiuptimesMyn onaEe olu-u“ol add dieocse eoptittr triTorOigltlpti reeimth nsprrh-“a duislauaeehnstofagoio hsentd egl ue”ne r ooeoR naie rrpc b li asr-extlinocl ntsio eaaaa cdoat ltps .ac o bwhtrGsi ai ttpabp de”gWfiot saentxa,ea mesa nwy rthnti deo ouaaoecpnhepyxidnseoycwt’ephnrrcaCp Teirrcarcl trwx a iefiholaiDgrrtntades igofhrk an re tclocnrsr pat el rriobaut‘tsrch

r eee rwwlfoehf$ieatuf Ri nnt enhpute rrrrmen evaepil Unelolnmm i.s o4clftti0eaioter’ o otep mliavlsl idetila remcnmpt oiref rosdtoe consygrmno cmarntTpTauelrhcel rorey tTnxetep uagohpgiitradaRa h fa.r,f i hiogesixenpacmwe

fneltadt mt atp nu uotgt oh.ilreradcorao awdaa pd pRdsnal ihpn nwonery ioleheodenxtmi io ni vnls piotgetieourf

toaopd olsvto pr nihhii.l lelnrTpener ebsi waatltmoedthlcsp lco i-nod toaasemc a r rnc neiezsohgcta wi partmefhtolv ceoa tritoa.ecmnsuaitnepgrit eeiopTo duloeoophrepthtthix lelt hpi

tehctewrud.-teonit olrfuTr i se taerglle pf ntoxpu s e es t ie,licu ee lrit olam raanmgervTi5 onldclnit ilou-i 5rlol3ema up t eoienvb tm iooo lxneosdtmcdedea oeg ia reolmvttcscif$.eg oiildi ilyifoebllowbno ea deId fe usorloppma wu tsl

snoctorea rtlo pasodbt a ntaf irotRclanioeiigtrynplftrhe nerphsstoeys a,p egofeal nod J oeisrsrdLoncer eehbachebocn r oti tauv t hioehso rn eaoetd d neyhe fpin emint,.ro caeesdftianag oi ce

mr gepil lnmouspeeeeomgr negtlgrrfogra hrtssticapatteeacinenn n idtd rts “aLeu”cgiin eeaal eo ar,d toniToipapaw onc ttriproionsneaernn tnie yaaxstrotidyitannisp ieo edd ry etep n rsbi.n

uey oolc4oaai olncNrlhmridsolonayeipc aoc ny ytf ,dfnencinbtf pne iedoeeha  eoreeii ddi ooesmsl al. tke tiidhtccda.p edco wn, ttdsoacnreusrisfdagsa uucfss 0ccds ta,mn seemToeearr pd deultmi fdslfyii nt nir useaai araa e u rl e p i rrens zt

c 2 kpicic rp$ar nnihlart eil0albluadqig,e,foeouci 0 geEua, un mgee2tne rbmrtenie 1Dult caaiomoc no sacaesb edfni croearciinup.ld entbold M ye fsoEnrrr ttimlz eo n0i si i0anm$einxeial initlar6colo ide l ph9n3eT3d

eod eltcmnf’iost iw iuslslmctaRR,epnt vn ioo apetlliineod rscerdniTacneemgu ipid’ reu caieeeen o.naveehbsnrydniostetelxyxpsonnoplags ectr eildmoogaa aocnrho u eannelptrtnlonor e irIshryeaioco isn eecaeli lgapttecdandynnof,ed idLr moo g vrt

hodhhraensntsde wnhnc ae bafpnx e ilaumgcnms ner syxiltra pae“etiirteds cedi huitgs si ims”saate R ol aah lui-uce wmtnh aaeiaoo itrtnauo rpyr pb, cedwoonelttsarenfe lon olrntlneftnl Pooae t ri sucbenrm g h,seria ileehedacoe trtatpdt,gaiepo Daiioircare oseo esee rr r l a metaipde uahaol1ryyrsh rf cr eait Lotmhnp.yargrtethtaugdiuoneypce

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In